SEC Form 4 · accession 0001104659-26-070090
ProQR Therapeutics N.V. · PRQR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Gylvin Lykke Hinsch
Director
Period of report
Jun 2, 2026
Accepted (ET)
Jun 3, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001612940
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1,F2 | $1.42 | Jun 2, 2026 | A | 14,495 | A | — | Jun 1, 2036 | Ordinary Shares | 14,495 | 14,495 | D |
Explanation of responses
- F1The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy.
- F225% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.